In addition to KRAS, alterations of the TP53, CDKN2A/B, and the MAPK/ERK pathway have been significantly correlated with worse survival in CCA, with no OS difference with respect to the tumor location among iCCA, eCCA, and gall bladder [56,68]. This evidence concerns the gene KRAS and cholangiocarcinoma.